Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Randomized Comparing Docetaxel, Doxorubicin and Cyclophosphamide (TAC) vs 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Patients With Negative Axillary Lymph Nodes
Brief Summary: This is a prospective, non-blinded randomized phase III trial. Patients will be post-surgically stratified at inclusion first according to the participating institution, then according to menopausal status and will be randomly assigned to receive either:

* TAC: Docetaxel 75 mg/m2 as a 1 hour intravenous (i.v.) infusion on day 1 every 3 weeks (q3w) in combination with doxorubicin 50 mg/m2 as an i.v. bolus and cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks.
* FAC: 5-fluorouracil 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks in combination with doxorubicin 50 mg/m2 as an i.v. bolus and cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks.


Options:
A: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxorubicin hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Arm A: FAC; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-fluorouracil, Drug: Doxorubicin, Drug: Cyclophosphamide | Arm Label: Arm B: TAC; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel, Drug: Doxorubicin, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: TAC | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Arm A: FAC | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Arm A: FAC, Arm B: TAC | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A: FAC, Arm B: TAC
C: Arm Label: Arm A Taxane-containing; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Arm B standard anthracyclin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel; Assigned to Arm(s): Arm A Taxane-containing, Arm B standard anthracyclin
D: Arm Label: Doxorubicin/cyclophosphamide, ixabepilone; Type: EXPERIMENTAL; Interventions: Drug: Doxorubicin, Drug: Cyclophosphamide, Drug: Ixabepilone (Ixempra) | Arm Label: Doxorubicin/cyclophosphamide, paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxorubicin, Drug: Cyclophosphamide, Drug: Paclitaxel (Taxol) | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Doxorubicin/cyclophosphamide, ixabepilone, Doxorubicin/cyclophosphamide, paclitaxel | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Doxorubicin/cyclophosphamide, ixabepilone, Doxorubicin/cyclophosphamide, paclitaxel | Intervention Type: DRUG; Name: Ixabepilone (Ixempra); Assigned to Arm(s): Doxorubicin/cyclophosphamide, ixabepilone | Intervention Type: DRUG; Name: Paclitaxel (Taxol); Assigned to Arm(s): Doxorubicin/cyclophosphamide, paclitaxel

Answer: B